Clinical Trials | February 17, 2026
Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Iberdomide has the potential to be the first approved CELMoD agent
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Subscribe To Our Newsletter & Stay Updated
